JOHANNESBURG, March 9 South African drugmaker
Aspen Pharmacare Holdings Ltd reported a 6 percent rise
in first-half profit on Thursday, helped by the results of a
recently acquired portfolio of medicines from AstraZeneca
Aspen, the biggest generic drugmaker in the southern
hemisphere, said normalised headline earnings per share rose to
692 cents in the six months ended December 2016, from 656 cents
a year earlier.
Headline EPS is the main profit measure in South Africa and
strips out certain one-off items.
Aspen said the results were largely boosted by the $770
million acquisition of marketing rights to a portfolio of
anaesthetics from AstraZeneca in September last year.
(Reporting by Tiisetso Motsoeneng; Editing by Subhranshu Sahu)